Reviewed listing: NASDAQ:PTGX · Analysis dated Oct 13, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Protagonist develops medicines for inflammatory, blood, and metabolic diseases. For its active substances licensed to large pharmaceutical partners, the company receives contractual payments and a share of drug sales.
What supports the business?
Two drugs originating from the company’s own research are now approved in the United States. Marketing by Johnson & Johnson and Takeda opens up revenue from their sales without requiring the company to build a large sales force of its own.
What could improve?
Rising sales of the two approved drugs could significantly increase recurring revenue. Additional approved uses and successful new active ingredients would create further value, but are not yet assured.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At 144.88 USD, the entire equity is worth roughly 9.37 billion USD by calculation. This price requires substantial long-term business success; at present, it does not support a sufficiently robust positive price assessment.
What is the main risk?
Drug sales must first provide sufficiently high, recurring revenue while Protagonist puts more money into new research. The high quarterly profit comes mostly from a one-time contractual payment and cannot simply be projected forward.
What is the overall assessment?
Protagonist has completed an important business transition with two US-approved partner products. However, at the specified price of 144.88 USD, the balance of long-term revenue potential, research burden, and success already priced in is not yet compelling enough: watch because price support is unclear, not because of a material data gap.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · api-v4.fcsapi.com
- Original source 2 · data.sec.gov
- Original source 3 · www.sec.gov · Aug 05, 2026
- Original source 4 · www.nasdaq.com · Aug 05, 2026
- Original source 5 · www.takeda.com · Aug 28, 2026
- Original source 6 · irp.cdn-website.com · Sep 08, 2026
- Original source 7 · www.takedaoncology.com · Sep 21, 2026
- Original source 8 · www.sec.gov